MKI67 and breast carcinoma: Particularly noteworthy is also the fact that ki-67 staining is related to overall survival in breast cancer patients and that several clinical applications are integrated within the standard routine: On the one hand, ki-67 is used to define the intrinsic subtype (luminal A / luminal B tumors) of breast cancer; on the other hand, it can be used (together with other parameters) for risk assessment and identification of patients who benefit from chemotherapeutical treatment in addition to endocrine therapy.